Daniel L. Brinton
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Daniel L. Brinton has a total of 84 co-authors. Here are the top co-authors by number of shared publications:
- Annie N. Simpson
Department of Health Sciences and Research, Medical University of South Carolina, Charleston, South Carolina
8 shared publications - Dee Walker Ford
Department of Pulmonary and Critical Care Medicine, Center for Telehealth, Medical University of South Carolina, Charleston, SC 29425, USA
8 shared publications - Andrew J. Goodwin
Div of Pulmonary Critical Care Allergy & Sleep Med, Medical University of South Carolina, Charleston, SC, United States
6 shared publications - Kit N. Simpson
Medical University of South Carolina
4 shared publications Annie N. Simpson
Department of Healthcare Leadership and Management, College of Healthcare Professions, Medical University of South Carolina, Charleston, USA
3 shared publications- Emily Johnson
College of Nursing, Medical University of South Carolina, Charleston, South Carolina, USA
3 shared publications
Latest Publications
- Open Access
- 23 March 2026
- Published by Springer Nature in Cost Effectiveness and Resource Allocation
- Vol. 24
A Markov modeling framework for estimating the effects of asthma medication adherence on healthcare use and costs in pediatric asthma
Asthma medication adherence, measured by the asthma medication ratio (AMR), has been shown to be a reliable predictor of exacerbations among children with
- 23 March 2026
- Published by Springer Nature in Cost Effectiveness and Resource Allocation
- Vol. 24
Open AccessA Markov modeling framework for estimating the effects of asthma medication adherence on healthcare use and costs in pediatric asthma
Asthma medication adherence, measured by the asthma medication ratio (AMR), has been shown to be a reliable predictor of exacerbations among children with
- Open Access
- 25 August 2025
- Published by AccScience Publishing in Journal of Clinical and Translational Research
- Vol. 11 (5) , 106
Prospective evaluation of the adapted Ontario Protocol Assessment Level score for predicting clinical research coordinator workload: An internal validation study
Background: The escalating complexity of clinical trial protocols has considerably increased the workload for research coordinators, exacerbating staffing shortages and contributing to operational inefficiencies. These challenges are particularly pronounced at under-resourced and minority-serving research institutions, where limited capacity may hinder the implementation of trials. Early and accurate estimation of research coordinator effort is essential for effective planning, resource management, and successful clinical trial conduct. Aim: This study assesses the accuracy of an adopted Ontario Protocol Assessment Level (OPAL) score in predicting coordinator workload to improve operational planning in clinical research. Methods: A prospective observational study was conducted over a 12-month period at a Historically Black College and University medical school. Seven coordinators recorded hours for seven actively enrolling interventional trials. Estimated workloads were calculated using a published, adapted OPAL reference table, and were compared with actual hours using descriptive statistics and paired t-tests. To ensure consistent benchmarking, workday equivalencies (7.5 h for institutional standards and 8 h for industry standards) were applied. Results: There was no statistically significant difference between estimated and actual hours, with an average difference of 24.1 h (p=0.761). The mean absolute error was 167.0 h, equivalent to roughly 1 month of full-time work. Conclusion: The adapted OPAL score provides a practical tool for estimating coordinator workload and aligning staffing with protocol complexity, including in under-resourced settings. However, broader multi-site validation is required to confirm its generalizability and to support its integration into feasibility planning. Relevance for patients: Accurate workload forecasting enhances trial efficiency, supporting timely, high-quality studies, and accelerating access to new treatments.
- 25 August 2025
- Published by AccScience Publishing in Journal of Clinical and Translational Research
- Vol. 11 (5) , 106
Open AccessProspective evaluation of the adapted Ontario Protocol Assessment Level score for predicting clinical research coordinator workload: An internal validation study
Background: The escalating complexity of clinical trial protocols has considerably increased the workload for research coordinators, exacerbating staffing shortages and contributing to operational inefficiencies. These challenges are particularly pronounced at under-resourced and minority-serving research institutions, where limited capacity may hinder the implementation of trials. Early and accurate estimation of research coordinator effort is essential for effective planning, resource management, and successful clinical trial conduct. Aim: This study assesses the accuracy of an adopted Ontario Protocol Assessment Level (OPAL) score in predicting coordinator workload to improve operational planning in clinical research. Methods: A prospective observational study was conducted over a 12-month period at a Historically Black College and University medical school. Seven coordinators recorded hours for seven actively enrolling interventional trials. Estimated workloads were calculated using a published, adapted OPAL reference table, and were compared with actual hours using descriptive statistics and paired t-tests. To ensure consistent benchmarking, workday equivalencies (7.5 h for institutional standards and 8 h for industry standards) were applied. Results: There was no statistically significant difference between estimated and actual hours, with an average difference of 24.1 h (p=0.761). The mean absolute error was 167.0 h, equivalent to roughly 1 month of full-time work. Conclusion: The adapted OPAL score provides a practical tool for estimating coordinator workload and aligning staffing with protocol complexity, including in under-resourced settings. However, broader multi-site validation is required to confirm its generalizability and to support its integration into feasibility planning. Relevance for patients: Accurate workload forecasting enhances trial efficiency, supporting timely, high-quality studies, and accelerating access to new treatments.
- Open Access
- 11 March 2025
- Published by Wiley in Psychology in the Schools
- Vol. 62 (8) , 2362-2372
Addressing Gaps in Pediatric Mental Healthcare by Removing Barriers: A School‐Based Integrated Model for Group Art Therapy
In the fall of 2021, experts declared a national emergency in children's mental health, urging organizations to put in place school‐based mental health care services to reduce barriers and increase access to care. This paper describes implementation and acceptability of an innovative school‐based model to deliver group art therapy that is integrated into the school's Muti‐Tiered System of Supports, and changes in student social‐emotional competencies that occurred in association with participation. The 7‐week pilot was implemented in three successive semesters, serving 280 elementary students. Guardians completed Strengths and Difficulties Questionnaires (SDQ) before and after the intervention to describe changes in student social‐emotional competencies. SDQ data suggest improvement in internalizing symptoms amongst participants (n = 17, mean decrease in 1.7 points [95% CI: 0.2–3.2]; p = 0.0314). Guardians surveyed (n = 12) strongly agreed that art therapy programs should be continued in the school and that the art therapy process gave their child an alternative form of safe expression [4.88 and 4.75 out of 5 (SD = 0.14 and 0.29), respectively]. All students completed the program. Cost was $170.00 per child. This school‐based group art therapy model was found feasible and acceptable, and if scaled, can impact a large population of children with barriers to mental healthcare access.
- 11 March 2025
- Published by Wiley in Psychology in the Schools
- Vol. 62 (8) , 2362-2372
Open AccessAddressing Gaps in Pediatric Mental Healthcare by Removing Barriers: A School‐Based Integrated Model for Group Art Therapy
In the fall of 2021, experts declared a national emergency in children's mental health, urging organizations to put in place school‐based mental health care services to reduce barriers and increase access to care. This paper describes implementation and acceptability of an innovative school‐based model to deliver group art therapy that is integrated into the school's Muti‐Tiered System of Supports, and changes in student social‐emotional competencies that occurred in association with participation. The 7‐week pilot was implemented in three successive semesters, serving 280 elementary students. Guardians completed Strengths and Difficulties Questionnaires (SDQ) before and after the intervention to describe changes in student social‐emotional competencies. SDQ data suggest improvement in internalizing symptoms amongst participants (n = 17, mean decrease in 1.7 points [95% CI: 0.2–3.2]; p = 0.0314). Guardians surveyed (n = 12) strongly agreed that art therapy programs should be continued in the school and that the art therapy process gave their child an alternative form of safe expression [4.88 and 4.75 out of 5 (SD = 0.14 and 0.29), respectively]. All students completed the program. Cost was $170.00 per child. This school‐based group art therapy model was found feasible and acceptable, and if scaled, can impact a large population of children with barriers to mental healthcare access.
- Open Access
- 5 December 2024
- Published by Springer Nature in Journal of Perinatology
- Vol. 45 (1) , 94-100
Acute kidney injury associated with increased costs in the neonatal intensive care unit: analysis of Pediatric Health Information System database
Objective: Compare neonatal intensive care unit hospitalization costs between neonates with and without AKI; identify predictors of AKI-associated costs. We hypothesized neonates with AKI would amass more costs than those without AKI. Study design: Retrospective, multicenter cohort study of surviving neonates cared for 2015–2021 in Pediatric Health Information System database. The primary outcome was estimated hospitalization costs. Results: Data from 304,725 neonates were evaluated, 8774 (3%) with AKI and 295,951 (97%) without AKI. Neonates with AKI had $58,807 greater adjusted costs than those without AKI. AKI-associated costs were most strongly driven by Feudtner Pediatric Complex Chronic Conditions Classifications (cardiovascaular, congenital/genetic, gastrointestinal, medical technology) and gestational age. Adjusted costs decreased with increasing gestational age, regardless of AKI status. Conclusions: AKI is independently associated with increased hospital costs. Knowledge of these drivers can help in identifying high-value practices for cost mitigation strategies.
- 5 December 2024
- Published by Springer Nature in Journal of Perinatology
- Vol. 45 (1) , 94-100
Open AccessAcute kidney injury associated with increased costs in the neonatal intensive care unit: analysis of Pediatric Health Information System database
Objective: Compare neonatal intensive care unit hospitalization costs between neonates with and without AKI; identify predictors of AKI-associated costs. We hypothesized neonates with AKI would amass more costs than those without AKI. Study design: Retrospective, multicenter cohort study of surviving neonates cared for 2015–2021 in Pediatric Health Information System database. The primary outcome was estimated hospitalization costs. Results: Data from 304,725 neonates were evaluated, 8774 (3%) with AKI and 295,951 (97%) without AKI. Neonates with AKI had $58,807 greater adjusted costs than those without AKI. AKI-associated costs were most strongly driven by Feudtner Pediatric Complex Chronic Conditions Classifications (cardiovascaular, congenital/genetic, gastrointestinal, medical technology) and gestational age. Adjusted costs decreased with increasing gestational age, regardless of AKI status. Conclusions: AKI is independently associated with increased hospital costs. Knowledge of these drivers can help in identifying high-value practices for cost mitigation strategies.
- Open Access
The Use of Wearable Sensors and Machine Learning Methods to Estimate Biomechanical Characteristics During Standing Posture or Locomotion: A Systematic Review
Balance deficits are present in a variety of clinical populations and can negatively impact quality of life. The integration of wearable sensors and machine learning technology (ML) provides unique opportunities to quantify biomechanical characteristics related to balance outside of a laboratory setting. This article provides a general overview of recent developments in using wearable sensors and ML to estimate or predict biomechanical characteristics such as center of pressure (CoP) and center of mass (CoM) motion. This systematic review was conducted according to PRISMA guidelines. Databases including Scopus, PubMed, CINHAL, Trip PRO, Cochrane, and Otseeker databases were searched for publications on the use of wearable sensors combined with ML to predict biomechanical characteristics. Fourteen publications met the inclusion criteria and were included in this review. From each publication, information on study characteristics, testing conditions, ML models applied, estimated biomechanical characteristics, and sensor positions were extracted. Additionally, the study type, level of evidence, and Downs and Black scale score were reported to evaluate methodological quality and bias. Most studies tested subjects during walking and utilized some type of neural network (NN) ML model to estimate biomechanical characteristics. Many of the studies focused on minimizing the necessary number of sensors and placed them on areas near or below the waist. Nearly all studies reporting RMSE and correlation coefficients had values 0.85, respectively, indicating strong ML model estimation accuracy. Overall, this review can help guide the future development of ML algorithms and wearable sensor technologies to estimate postural mechanics.
Open AccessThe Use of Wearable Sensors and Machine Learning Methods to Estimate Biomechanical Characteristics During Standing Posture or Locomotion: A Systematic Review
Balance deficits are present in a variety of clinical populations and can negatively impact quality of life. The integration of wearable sensors and machine learning technology (ML) provides unique opportunities to quantify biomechanical characteristics related to balance outside of a laboratory setting. This article provides a general overview of recent developments in using wearable sensors and ML to estimate or predict biomechanical characteristics such as center of pressure (CoP) and center of mass (CoM) motion. This systematic review was conducted according to PRISMA guidelines. Databases including Scopus, PubMed, CINHAL, Trip PRO, Cochrane, and Otseeker databases were searched for publications on the use of wearable sensors combined with ML to predict biomechanical characteristics. Fourteen publications met the inclusion criteria and were included in this review. From each publication, information on study characteristics, testing conditions, ML models applied, estimated biomechanical characteristics, and sensor positions were extracted. Additionally, the study type, level of evidence, and Downs and Black scale score were reported to evaluate methodological quality and bias. Most studies tested subjects during walking and utilized some type of neural network (NN) ML model to estimate biomechanical characteristics. Many of the studies focused on minimizing the necessary number of sensors and placed them on areas near or below the waist. Nearly all studies reporting RMSE and correlation coefficients had values 0.85, respectively, indicating strong ML model estimation accuracy. Overall, this review can help guide the future development of ML algorithms and wearable sensor technologies to estimate postural mechanics.
- Open Access
- 4 September 2024
- Published by Springer Nature in Research Square
A Markov Model for Estimating Medication Adherence Effect on Pediatric Asthma Healthcare Use and Cost
Background/Objective: Asthma medication adherence, measured by the asthma medication ratio (AMR), has been shown to be a reliable predictor of exacerbations among children with asthma. We estimated the effects of optimal vs suboptimal AMR on exacerbations resulting in an emergency department (ED) visit or inpatient (IP) admission. Methods : We constructed an asthma Markov model using claims for a cohort of Medicaid beneficiaries aged 2‐17 years (n = 214,452) using 2013‐2014 MarketScan® data who had at least one claim for an inhaled corticosteroid. We calculated 3‐month AMRs as the basis of transition estimates in the model. The AMRs data were transformed to reflect a one‐month Markov cycle length. Our model included five states: controlled, sub optimally controlled, inactive, IP admission, and ED. The Markov model used an overall 2‐year time horizon for 10,000 beneficiaries. Patients entered the model in one of the five states as observed in the Medicaid data. Costs were based on 2017 Medicaid claims adjusted to reflect 2019 costs. Asthma medication cost-weight were mean payments observed for controller or rescue drugs, and costs weights for an ED visit or inpatient admission used median payments. Utilities for each state were based on existing literature. Results : Monthly costs for children with asthma were $214 for controlled, $32 for suboptimally controlled (attributable to fewer medication fills), $565 for months with ED visit, and $5,883 with admission. Over a 2‐year period, we estimated the 2‐year direct medical costs of asthma among Medicaid insured children to average $4,552 per child. Children are on average 1.6 months more in controlled state at a cost of $0.71 more per child per month accounting for medication cost less the cost of ED visits and hospitalizations. In addition to the saved side effects of oral steroids and time hospitalized, there is one increased quality month per 13 months. Conclusions : This Markov model populated with Medicaid population exacerbation, ED, hospital and medication use and payment data provides a solid framework to examine the cost effectiveness of existing and novel targeted interventions aimed at improving medication adherence and decreasing acute care visits for Medicaid children with asthma.
- 4 September 2024
- Published by Springer Nature in Research Square
Open AccessA Markov Model for Estimating Medication Adherence Effect on Pediatric Asthma Healthcare Use and Cost
Background/Objective: Asthma medication adherence, measured by the asthma medication ratio (AMR), has been shown to be a reliable predictor of exacerbations among children with asthma. We estimated the effects of optimal vs suboptimal AMR on exacerbations resulting in an emergency department (ED) visit or inpatient (IP) admission. Methods : We constructed an asthma Markov model using claims for a cohort of Medicaid beneficiaries aged 2‐17 years (n = 214,452) using 2013‐2014 MarketScan® data who had at least one claim for an inhaled corticosteroid. We calculated 3‐month AMRs as the basis of transition estimates in the model. The AMRs data were transformed to reflect a one‐month Markov cycle length. Our model included five states: controlled, sub optimally controlled, inactive, IP admission, and ED. The Markov model used an overall 2‐year time horizon for 10,000 beneficiaries. Patients entered the model in one of the five states as observed in the Medicaid data. Costs were based on 2017 Medicaid claims adjusted to reflect 2019 costs. Asthma medication cost-weight were mean payments observed for controller or rescue drugs, and costs weights for an ED visit or inpatient admission used median payments. Utilities for each state were based on existing literature. Results : Monthly costs for children with asthma were $214 for controlled, $32 for suboptimally controlled (attributable to fewer medication fills), $565 for months with ED visit, and $5,883 with admission. Over a 2‐year period, we estimated the 2‐year direct medical costs of asthma among Medicaid insured children to average $4,552 per child. Children are on average 1.6 months more in controlled state at a cost of $0.71 more per child per month accounting for medication cost less the cost of ED visits and hospitalizations. In addition to the saved side effects of oral steroids and time hospitalized, there is one increased quality month per 13 months. Conclusions : This Markov model populated with Medicaid population exacerbation, ED, hospital and medication use and payment data provides a solid framework to examine the cost effectiveness of existing and novel targeted interventions aimed at improving medication adherence and decreasing acute care visits for Medicaid children with asthma.
- 2 March 2024
- Published by Elsevier in Academic Pediatrics
- Vol. 24 (5) , 783-790
Persistent Opioid Use Following Pediatric Nonfatal Firearm Injury
- 2 March 2024
- Published by Elsevier in Academic Pediatrics
- Vol. 24 (5) , 783-790
Persistent Opioid Use Following Pediatric Nonfatal Firearm Injury
- Open Access
- 3 November 2022
- Published by Springer Nature in Journal of Perinatology
- Vol. 42 (12) , 1714
Correction to: Costs associated with acute kidney injury in critically Ill neonates with patent Ductus arteriosus: pediatric health information system (PHIS) analysis
- 3 November 2022
- Published by Springer Nature in Journal of Perinatology
- Vol. 42 (12) , 1714
Open AccessCorrection to: Costs associated with acute kidney injury in critically Ill neonates with patent Ductus arteriosus: pediatric health information system (PHIS) analysis
- 7 September 2022
- Published by Springer Nature in Journal of Perinatology
- Vol. 42 (12) , 1669-1673
Costs associated with acute kidney injury in critically Ill neonates with patent Ductus arteriosus: pediatric health information system (PHIS) analysis
Objective Compare costs of hospitalization between critically-ill neonates with patent ductus arteriosus (PDA) who did and did not develop acute kidney injury (AKI). Study design Using the Children’s Hospital Association’s Pediatric Health Information System (PHIS) database, we ascertained the marginal estimated total cost of hospitalization between those who did and did not develop AKI. Results Query of 49 PHIS centers yielded 14,217 neonates with PDA, 1697 with AKI and 12,520 without AKI. Predictors of cost included AKI, birth weight, ethnicity, race, length of stay (LOS), and Feudtner Complex Chronic Conditions Classification System. LOS was the strongest predictor (AKI: median 71 days [IQR 28–130]; No AKI: 28 days [10–76]; p < 0.01). Neonates with AKI had $48,416 greater costs (95% CI: $43,804–53,227) after adjusting for these predictors (AKI: $190,063, 95% CI $183,735–196,610; No AKI: $141,647, 95% CI $139,931–143,383 l; p < 0.01). Conclusion AKI is independently associated with increased hospital costs in critically-ill neonates with PDA.
- 7 September 2022
- Published by Springer Nature in Journal of Perinatology
- Vol. 42 (12) , 1669-1673
Costs associated with acute kidney injury in critically Ill neonates with patent Ductus arteriosus: pediatric health information system (PHIS) analysis
Objective Compare costs of hospitalization between critically-ill neonates with patent ductus arteriosus (PDA) who did and did not develop acute kidney injury (AKI). Study design Using the Children’s Hospital Association’s Pediatric Health Information System (PHIS) database, we ascertained the marginal estimated total cost of hospitalization between those who did and did not develop AKI. Results Query of 49 PHIS centers yielded 14,217 neonates with PDA, 1697 with AKI and 12,520 without AKI. Predictors of cost included AKI, birth weight, ethnicity, race, length of stay (LOS), and Feudtner Complex Chronic Conditions Classification System. LOS was the strongest predictor (AKI: median 71 days [IQR 28–130]; No AKI: 28 days [10–76]; p < 0.01). Neonates with AKI had $48,416 greater costs (95% CI: $43,804–53,227) after adjusting for these predictors (AKI: $190,063, 95% CI $183,735–196,610; No AKI: $141,647, 95% CI $139,931–143,383 l; p < 0.01). Conclusion AKI is independently associated with increased hospital costs in critically-ill neonates with PDA.